DHEAS Levels in Non-Classic Congenital Adrenal Hyperplasia
DHEAS levels are typically elevated in NCCAH, but DHEAS alone is insufficient for diagnosis—the definitive test is an ACTH-stimulated 17-hydroxyprogesterone (17-OHP) level >1000-1500 ng/dL, with baseline 17-OHP >200 ng/dL being highly suggestive.
Diagnostic Approach to NCCAH
Primary Diagnostic Criteria
The diagnosis of NCCAH requires hormonal confirmation through specific testing protocols, not simply elevated DHEAS:
- Baseline 17-OHP levels >200 ng/dL are sufficient for diagnosis in most cases of NCCAH, particularly when clinical features are present 1
- ACTH stimulation testing (25 IU IV) is the gold standard when baseline 17-OHP is moderately elevated (100-300 ng/dL), with stimulated 17-OHP levels >1000 ng/dL confirming NCCAH 1
- DHEAS is included in hormonal screening panels for hyperandrogenism but is not diagnostic by itself 2
Role of DHEAS in NCCAH
While DHEAS is elevated in NCCAH, its utility is limited:
- DHEAS levels of 651 ± 256 ng/mL have been reported in NCCAH patients with precocious pubarche, compared to 506 ± 462 ng/mL in idiopathic precocious pubarche 1
- DHEAS elevation of 28.1% above controls was observed in untreated NCCAH women in a recent study 3
- DHEAS responds sluggishly to treatment changes, being elevated (>100 μg/dL) only in significantly undertreated patients, making it unreliable for monitoring disease control 4
- Not all NCCAH patients present with elevated DHEAS, limiting its screening value 4
Clinical Context for Testing
When to Suspect NCCAH
Endocrinologic evaluation for NCCAH is warranted in specific clinical scenarios:
In postpubertal females with signs of hyperandrogenism including 2:
- Hirsutism (60-80% of NCCAH cases) 5
- Recalcitrant acne (30% of cases) 5
- Androgenetic alopecia
- Menstrual irregularities (56% of cases) 5
- Infertility
In prepubertal children presenting with 2:
- Precocious pubarche
- Early-onset body odor
- Accelerated growth with advanced bone age
- Clitoromegaly (6-20% of female cases) 5
In males, NCCAH often remains asymptomatic and is typically diagnosed through family screening or fertility evaluations 5
Comprehensive Hormonal Panel
A typical screening panel for suspected NCCAH includes 2:
- 17-hydroxyprogesterone (baseline and ACTH-stimulated)
- Free and total testosterone
- DHEA-S
- Androstenedione
- Luteinizing hormone
- Follicle-stimulating hormone
Differential Diagnosis Considerations
NCCAH must be distinguished from polycystic ovary syndrome (PCOS), as clinical presentations overlap significantly:
- NCCAH women show less severe metabolic derangement than PCOS patients, with lower insulin levels (-28.5%) and HOMA-IR (-31.8%) compared to PCOS 3
- Both conditions present with elevated androgens, but the pattern differs—NCCAH shows characteristic 17-OHP elevation 3
- The differential diagnosis also includes thyroid disease and prolactin excess 2
Important Caveats
Limitations of DHEAS Testing
- Day-to-day variations can be considerable in certain populations, though generally small in children and during puberty 6
- No significant diurnal variation exists for DHEAS (0900h vs 1700h measurements are comparable) 6
- DHEAS correlates with urinary 17-ketosteroids (r=0.789) but this doesn't improve diagnostic accuracy for NCCAH specifically 6
Ethnic Considerations
NCCAH prevalence varies dramatically by ethnicity, affecting pre-test probability 5:
- Ashkenazi Jews: 3.7%
- Other Caucasian populations: 0.1%
This ethnic variation should inform the threshold for pursuing diagnostic testing when DHEAS and other androgens are borderline elevated.